AEZS ( MC $43 M) 8 Drugs in P2 /1 Drug in P3 / 1x Awaiting FDA approval

[Biotechmaster]

Here is a real Big Opportunity which you can buy currently at All Time Low ,the only reason for the very low price was just a Share offering a few weeks ago .

AEZS has already a Drug on the Market which is partnered with pharma giant Merck (MRK) , the annual revenue for the product is around $70 M thats almost two times higher than current Market Cap .

AEZS has another Drug awaiting FDA approval and muliple Cancer Drugs in Late Stage some of them a potential Blockbusters .

I think AEZS has the potential for runup to minimum to $4-5 before FDA decision in Mid 2014 . GL



AEterna Zentaris (AEZS)

Market Cap: $43 M
Cash: $24 M
Price: $1.35

Shares Out: 32 M

Annual Revenue :$ 70 M


MEGA Pipeline



New Presentation



Fact Sheet



PIPELINE :

Macimorelin Acetate (AEZS-130)

Diagnostic in adult growth hormonedeficiency (endocrinology) under review by FDA

Product ..Zoptarelin Doxorubicin (AEZS-108)

Endometrial cancer in Phase 3

Tripl-negative breast cancer In Phase 2

Castration-and taxane-resistant prostate cancer in Phase 2

Refractory bladder cancer in Phase 2

Ovarian cancer (completed) in Phase 2

Product ..Ozarelix :

Prostate cancer in Phase 2

Product ..Macimorelin Acetate (AEZS-130)

Therapeutic in cancer cachexia in Phase 2

Product ..Perifosine

Multiple cancers in Phase 2